Supernus (SUPN) AI Stock Analysis

0 Followers

Supernus

(BMV:SUPN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

SUBLOCADE growth and profitabilitySUBLOCADE is showing strong commercial momentum alongside expanding profitability, supporting durable earnings growth rather than relying solely on cost reduction. Continued patient adoption and higher margins can strengthen internal cash generation and fund investment across Indivior’s broader addiction-treatment portfolio.

Negative Factors

Negative shareholders’ equityNegative equity is a structural balance-sheet weakness that makes leverage metrics less informative and reduces financial resilience. Combined with sizable debt, it leaves less flexibility to absorb weaker profitability or cash flow and could constrain capital allocation during business setbacks.

Supernus (SUPN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 1.65B
Dividend Yield: 31.08%
Average Volume (3M): ―
Price to Earnings (P/E): 9.9
Beta (1Y): 0.13
Revenue Growth: 4.61%
EPS Growth: 226.72%
Country: Mexico
Employees: 827
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Supernus Business Overview & Revenue Model

Company Description

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and...

Supernus Risk Analysis

Supernus disclosed 22 risk factors in its most recent earnings report. Supernus reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Supernus Peers Comparison

Overall Rating

Financial Indicators

MX:SUPN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:SUPN and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	MX:SUPN	Supernus, Inc.	600.10	106.55	21.59%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Supernus AI Stock Analysis